XML 63 R50.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Significant Agreements - Additional Information (Details) - USD ($) |  | 1 Months Ended
--- | --- | ---
Jul. 31, 2020 | Jun. 30, 2020 | Sep. 30, 2018
Maximum | License Agreement | Novartis International Pharmaceuticals Limited |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Contingent development and sales milestone payments |  |  | $ 29,000,000.0
GSK Collaboration Agreement | GSK |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Upfront payment | $ 100,000,000.0 |  |
Number of days of notice period for terminating agreement |  | 90 days |
MAT2A Program |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Development costs sharing percentage |  | 20.00% |
Percentage of profit share |  | 50.00% |
MAT2A Program | Maximum |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Development and regulatory milestone payment eligible to receive |  | $ 465,000,000.0 |
Commercial milestone payment eligible to receive |  | 475,000,000.0 |
MAT2A Program | GSK |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Option exercise payment agreed to be received |  | $ 50,000,000.0 |
Development costs sharing percentage |  | 80.00% |
Pol Theta Program | Maximum |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Development and regulatory milestone payment eligible to receive |  | $ 485,000,000.0 |
Commercial milestone payment eligible to receive |  | $ 475,000,000.0 |
WRN Program |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Development costs sharing percentage |  | 20.00% |
Percentage of profit share |  | 50.00% |
WRN Program | Maximum |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Commercial milestone payment eligible to receive |  | $ 475,000,000.0 |
Development milestone payment eligible to receive |  | $ 485,000,000.0 |
WRN Program | GSK |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Development costs sharing percentage |  | 80.00% |

X
- Definition Commercial milestone payment to be received. + References No definition available. + Details
Name: | idya_CommercialMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contingent development and sales based milestone payments. + References No definition available. + Details
Name: | idya_ContingentDevelopmentAndSalesBasedMilestonePayments
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development and regulatory milestone payment to be received. + References No definition available. + Details
Name: | idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development costs sharing percentage. + References No definition available. + Details
Name: | idya_DevelopmentCostsSharingPercentage
Namespace Prefix: | idya_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development milestone payment to be received. + References No definition available. + Details
Name: | idya_DevelopmentMilestonePaymentToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of days of notice period for terminating collaboration agreement. + References No definition available. + Details
Name: | idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement
Namespace Prefix: | idya_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option exercise payment agreed to be received. + References No definition available. + Details
Name: | idya_OptionExercisePaymentAgreedToBeReceived
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of profit share. + References No definition available. + Details
Name: | idya_PercentageOfProfitShare
Namespace Prefix: | idya_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment. + References No definition available. + Details
Name: | idya_UpfrontPayment
Namespace Prefix: | idya_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=idya_NovartisInternationalPharmaceuticalsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_MethionineAdenosylTransferase2AProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |